These results allow concluding that the enzyme-responsive nanocarrier has the potential to considerably improve chemotherapy by selectively delivering cytostatic drugs to the nucleus of cathepsin B positive tumor cells and circumventing mechanisms of drug resistance. The gene discussed is CTSB; the disease is neoplasm.